Last reviewed · How we verify
Amniotic Suspension Allograft
Amniotic Suspension Allograft delivers amniotic membrane-derived cells and proteins to promote tissue repair and reduce inflammation.
Amniotic Suspension Allograft, developed by Organogenesis, is an investigational therapy for osteoarthritis and other musculoskeletal conditions. It is currently in Phase 3 and 4 trials, showing promise in reducing pain and improving function. The therapy leverages the regenerative properties of amniotic tissue, positioning it as a potential best-in-class treatment.
At a glance
| Generic name | Amniotic Suspension Allograft |
|---|---|
| Also known as | Rheo, Flowgraft |
| Sponsor | Organogenesis |
| Drug class | Amniotic membrane allograft |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Wound Care |
| Phase | Phase 3 |
Mechanism of action
This biologic product contains viable and non-viable amniotic cells, growth factors, and extracellular matrix components derived from donated amniotic membrane. It is designed to modulate the inflammatory response, promote angiogenesis, and support tissue regeneration at the site of application. The allograft provides a biological scaffold and bioactive factors that facilitate wound healing and tissue remodeling.
Approved indications
- Diabetic foot ulcers
- Chronic wounds
- Surgical wounds
Common side effects
- Infection at application site
- Allergic reaction
- Delayed wound healing